Sanofi analyst consensus on the Tuesday session, shares in the pharma peer comparison

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 12:48.

Sanofi (FR0000120578) stands in the Tuesday spotlight with its analyst consensus across major broker houses. The Paris-listed pharma group is a core component of European healthcare benchmarks such as the Stoxx Europe 600 and competes with peers Novartis and Roche in large-cap therapeutics coverage.

What analysts broadly signal

Broker coverage on Sanofi typically clusters around a mix of Buy and Hold ratings, reflecting the group’s position as a diversified, dividend-paying pharma name with exposure to specialty care, vaccines and general medicines. While I cannot fetch live reports today, recent patterns from major houses such as Goldman Sachs, UBS, JPMorgan and Deutsche Bank have historically shown a balanced stance between upside from the specialty pipeline and caution around patent cliffs.

Price targets from these houses usually span a moderate premium to the prevailing share price, indicating expectations of mid-single to low-double-digit total return potential when dividends are included. The dispersion of targets tends to be narrower than for more volatile biotech names, consistent with Sanofi’s profile as a mature Big Pharma issuer with substantial cash flows and established franchises.

Consensus structure on Sanofi

Typical consensus snapshots for Sanofi aggregate around the proportion of Buy, Hold and Sell ratings, average 12-month price target, and projected earnings per share growth over the next two to three years. In recent years, the majority of coverage has leaned toward Buy or Outperform, with a smaller cluster of Neutral or Hold ratings and only isolated Underperform calls.

On Tuesday, such a consensus snapshot matters for investors comparing Sanofi shares against other European pharma names. The group’s earnings profile, margin structure and capital allocation approach influence how analysts adjust models when new clinical data, regulatory decisions or pricing developments emerge in key markets such as the United States and the European Union.

The business behind the stock

Sanofi’s core business spans three major pillars: Specialty Care, Vaccines and General Medicines, supplemented by Consumer Healthcare activities. In Specialty Care, the group focuses on immunology, oncology, rare diseases and neurology, commercializing biologics and targeted therapies that address high unmet medical needs.

The Vaccines unit develops and supplies a broad range of pediatric and adult vaccines, including influenza, meningitis and booster formulations, serving public health systems and private markets worldwide. General Medicines covers established brands in cardiovascular, diabetes and other primary care segments, while Consumer Healthcare offers over-the-counter products in categories such as allergy, pain relief and digestive health.

Where the stock trades today

Sanofi shares (FR0000120578) are primarily listed on Euronext Paris, with the stock commonly referenced in European indices such as CAC 40 and Stoxx Europe 600. As live intraday data is not accessible in this context, the current price and exact timestamp cannot be stated, but the listing venue and currency reference remain Euronext Paris in euros.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data and assessments are based on publicly available information believed to be reliable at the time of writing, but their accuracy and completeness cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser before making investment decisions.